Clinical pearls and strategies to optimize patient outcomes

Diabetes Educator

Volumn 34, Issue 3, 2008, Pages

  Joy, Scott V ^a,b  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b Division of General Internal Medicine ^*

Author keywords

[No Author keywords available]

Indexed keywords

GLYCOSYLATED HEMOGLOBIN; INSULIN;

BLOOD; DIABETES MELLITUS; GLUCOSE BLOOD LEVEL; HUMAN; METABOLISM; MOTIVATION; PATIENT COMPLIANCE; PSYCHOLOGICAL ASPECT; REVIEW; SUBCUTANEOUS DRUG ADMINISTRATION;

BLOOD GLUCOSE; DIABETES MELLITUS; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; INJECTIONS, SUBCUTANEOUS; INSULIN; MOTIVATION; PATIENT COMPLIANCE;

EID: 44349185370     PISSN: 01457217     EISSN: 15546063     Source Type: Journal    
DOI: 10.1177/0145721708319233     Document Type: Review

References (30)

1. National Health and Nutrition Examination Survey (NHANES) 1999-2000. Hyattsville, MD: National Center for Health Statistics ; 2000.
2. Coffey RM, Matthews TL, McDermott K., for the Agency for Healthcare Research and Quality, US Department of Health and Human Services. Diabetes Care Quality Improvement: A Resource Guide for State Action. Rockville, MD: Agency for Healthcare Research and Quality, US Department of Health and Human Services ; 2004. AHRQ publication 04-0072.
3. National Health and Nutrition Examination Survey (NHANES) III. Hyattsville, MD: National Center for Health Statistics ; 1994.
4. Hoerger TJ, Segel JE, Gregg EW, Saaddine JB Is glycemic control improving in U.S. adults? Diabetes Care. 2008 ; 31: 81-86.
5. American Diabetes Association. Standards of medical care in diabetes. Diabetes Care. 2007 ; 30 (suppl 1). S4 - S41.
6. American Association of Clinical Endocrinologists. State of diabetes in America. Available at: http://www.aace.com/public/awareness/stateofdiabetes/ DiabetesAmericaReport.pdf. Accessed September 5, 2007.
7. Ho PM, Rumsfeld JS, Masoudi FA, et al. Effect of medication nonadherence on hospitalization and mortality among patients with diabetes mellitus. Arch Intern Med. 2006 ; 166: 1836-1841.
8. Rubin RR Adherence to pharmacologic therapy in patients with type 2 diabetes mellitus. Am J Med. 2005 ; 118: 27S - 34S.
9. Phillips LS, Branch WT Jr, Cook CB, et al. Clinical inertia. Ann Int Med. 2001 ; 135: 825-834.
10. Drass J., Kell S., Osborn M., et al. Diabetes care for Medicare beneficiaries: attitudes and behaviors of primary care physicians. Diabetes Care. 1998 ; 21: 1282-1287. Cited by: Phillips LS, Branch WT Jr, Cook CB, et al. Clinical inertia. Ann Int Med. 2001 ; 135: 825-834.
11. El-Kebbi IM, Ziemer DC, Gallina DL, Dunbar V., Phillips LS Diabetes in urban African-Americans: XV. Identification of barriers to provider adherence to management protocols. Diabetes Care. 1999 ; 22: 1617-1620.
12. Shah BR, Hux JE, Laupacis A., Zinman B., van Walraven C. Clinical inertia in response to inadequate glycemic control: do specialists differ from primary care physicians ? Diabetes Care. 2005 ; 28: 600-606.
13. Leslie CA, Satin-Rapaport W., Matheson D., Stone R., Enfield G. Psychological insulin resistance: a missed diagnosis ? Diabetes Spectrum. 1994 ; 7: 52-57.
14. Alberti G. The DAWN (Diabetes Attitudes, Wishes and Needs) study. Pract Diabetes Int. 2002 ; 19: 22a - 24a.
15. Van der Does, De Neeling JN, Snoek FJ, et al. Symptoms and well-being in relation to glycemic control in type II diabetes. Diabetes Care. 1996: 19 ; 204-210. Cited by: Korytkowski M. When oral agents fail: practical barriers to starting insulin. Int J Obes. 2002 ; 26 (suppl 3). S18 - S24.
16. Symlin [package insert]. San Diego, CA: Amylin Pharmaceuticals, Inc ; 2005.
17. Byetta [package insert]. San Diego, CA: Amylin Pharmaceuticals, Inc ; 2007.
18. NovoLog [package insert]. Princeton, NJ: Novo Nordisk Inc ; 2000.
19. Apidra [package insert]. Kansas City, MO: Aventis Pharmaceuticals Inc ; 2005.
20. Humalog [package insert]. Indianapolis, IN: Eli Lilly and Company ; 2003.
21. Novolin R [package insert]. Princeton, NJ: Novo Nordisk Inc ; 2005.
22. Novolin N [package insert]. Princeton, NJ: Novo Nordisk Pharmaceuticals, Inc ; 1999.
23. Levemir [package insert]. Princeton, NJ: Novo Nordisk Inc ; 2005.
24. Lantus [package insert]. Kansas City, MO: Aventis Pharmaceuticals Inc ; 2000.
25. Lukinius A., Korsgren O., Grimelius L., Wilander E. Expression of islet amyloid polypeptide in fetal and adult porcine and human pancreatic islet cells. Endocrinology. 1996 ; 137: 5319-5325.
26. Byetta Pen User Manual. San Diego, CA: Amylin Pharmaceuticals, Inc ; 2006.
27. American Diabetes Association. Insulin administration. Diabetes Care. 2003 ; 26 (suppl 1). S121 - S124.
28. Renders CM, Valk GD, Giffin SJ, Wagner EH, van Eijk JT, Assendelft WJJ. Interventions to improve the management of diabetes in primary care, outpatient, and community settings: a systematic review [review]. Diabetes Care. 2001 ; 24: 1821-1833.
29. Glasgow RE, Emont S., Miller DC Assessing delivery of the five 'As' for patient-centered counseling. Health Promot Int. 2006 ; 21: 245-255.
30. Rollnick S., Miller WR What is MI? Behav Cogn Psychother. 1995 ; 23: 325-334.